Zacks Research Has Bearish Estimate for MOH Q3 Earnings

Molina Healthcare, Inc (NYSE:MOH - Free Report) - Equities research analysts at Zacks Research lowered their Q3 2025 earnings estimates for Molina Healthcare in a report released on Thursday, July 17th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $5.71 for the quarter, down from their previous estimate of $5.72. The consensus estimate for Molina Healthcare's current full-year earnings is $24.40 per share. Zacks Research also issued estimates for Molina Healthcare's Q4 2025 earnings at $5.03 EPS, Q1 2026 earnings at $6.70 EPS, Q2 2026 earnings at $6.26 EPS, Q4 2026 earnings at $6.97 EPS, Q2 2027 earnings at $7.58 EPS and FY2027 earnings at $28.60 EPS.

Molina Healthcare (NYSE:MOH - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported $6.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.96 by $0.12. The company had revenue of $11.15 billion for the quarter, compared to analyst estimates of $10.86 billion. Molina Healthcare had a net margin of 2.81% and a return on equity of 28.38%. The business's quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the firm posted $5.73 earnings per share.

A number of other analysts have also issued reports on MOH. Truist Financial dropped their price objective on shares of Molina Healthcare from $400.00 to $335.00 and set a "buy" rating on the stock in a research note on Wednesday, July 16th. Robert W. Baird restated a "neutral" rating and issued a $375.00 price target (up previously from $331.00) on shares of Molina Healthcare in a research note on Tuesday, April 15th. Mizuho set a $330.00 target price on shares of Molina Healthcare and gave the company an "outperform" rating in a research note on Friday, July 11th. Barclays lowered their target price on shares of Molina Healthcare from $351.00 to $347.00 and set an "equal weight" rating for the company in a research note on Monday, June 9th. Finally, Morgan Stanley lowered shares of Molina Healthcare from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $364.00 to $266.00 in a research note on Thursday, July 10th. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Molina Healthcare presently has an average rating of "Hold" and a consensus target price of $347.57.

Molina Healthcare Trading Down 10.7%

MOH opened at $182.47 on Monday. The firm has a market capitalization of $9.89 billion, a P/E ratio of 8.81, a P/E/G ratio of 0.81 and a beta of 0.55. The firm's 50 day moving average is $281.73 and its 200-day moving average is $300.46. Molina Healthcare has a 52-week low of $182.09 and a 52-week high of $365.23. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.87.

Institutional Investors Weigh In On Molina Healthcare

Several institutional investors have recently bought and sold shares of MOH. Rothschild Investment LLC lifted its holdings in Molina Healthcare by 126.3% in the first quarter. Rothschild Investment LLC now owns 86 shares of the company's stock worth $28,000 after purchasing an additional 48 shares during the period. Zions Bancorporation National Association UT acquired a new stake in Molina Healthcare in the first quarter worth about $29,000. Colonial Trust Co SC lifted its holdings in Molina Healthcare by 930.0% in the fourth quarter. Colonial Trust Co SC now owns 103 shares of the company's stock worth $30,000 after purchasing an additional 93 shares during the period. Deseret Mutual Benefit Administrators lifted its holdings in Molina Healthcare by 60.7% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 90 shares of the company's stock valued at $30,000 after acquiring an additional 34 shares during the last quarter. Finally, Elequin Capital LP lifted its holdings in Molina Healthcare by 170.6% in the 1st quarter. Elequin Capital LP now owns 92 shares of the company's stock valued at $30,000 after acquiring an additional 58 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.

Insider Buying and Selling at Molina Healthcare

In other news, Director Richard M. Schapiro sold 669 shares of the business's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $320.50, for a total transaction of $214,414.50. Following the completion of the transaction, the director owned 11,244 shares of the company's stock, valued at approximately $3,603,702. The trade was a 5.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Joseph M. Zubretsky sold 87,500 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $320.06, for a total transaction of $28,005,250.00. Following the transaction, the chief executive officer directly owned 257,715 shares of the company's stock, valued at approximately $82,484,262.90. This trade represents a 25.35% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.26% of the company's stock.

Molina Healthcare Company Profile

Molina Healthcare, Inc provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.